Blocking of inhibitory adrenergic receptors by a dichloro analog of isoproterenol.

doi:10.1016/s0022-3565(25)12002-8

Paper

Blocking of inhibitory adrenergic receptors by a dichloro analog of isoproterenol.

Published Apr 1, 1958 · C. E. Powell, I. H. Slater, Lester LeCompte

The Journal of pharmacology and experimental therapeutics

Q2 SJR score

390

Citations

3

Influential Citations

Full textSemantic Scholar

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

Non-RCT

Animal Study

Highly Cited

Study Snapshot

The dichloro analog of isoproterenol selectively blocks some inhibitory effects of epinephrine and isoproterenol, potentially competing for these sites with physiologically active amines.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

Blocking of inhibitory adrenergic receptors by a dichloro analog of isoproterenol.

Sign up to use Study Snapshot

References

Citations

Sir James Whyte Black OM. 14 June 1924—22 March 2010

Sir James Whyte Black, a Scottish pharmacologist, won the 1988 Nobel Prize for his drug invention method, leading to beta-blockers and histamine H2-antagonists, revolutionizing treatments for angina, hypertension, and stomach ulcers.

Chemical Modeling: From Paul Ehrlich's Dyes to β-Blockers - A Brief History

Paul Ehrlich's dyes and side chains revolutionized chemical modeling, leading to the development of chemotherapeutic action and drug design in the twentieth century.

Pharmacological and Therapeutic Profiling in Drug Innovation: The Early History of the Beta Blockers

Drug innovation involves a complex interaction between basic and industrial research, with therapeutic context playing a crucial role in stimulating innovative drug research and clinical research contributing to drug development.

Treatment of chronic heart failure with β-adrenergic receptor antagonists: a convergence of receptor pharmacology and clinical cardiology.

-blockers have become the top treatment for chronic heart failure due to a 30-year research effort and a lack of systematic development plans.

ATP as a sympathetic neurotransmitter

ATP becomes a more important sympathetic neurotransmitter under conditions of raised vascular tone, as it enhances electrically-evoked responses in porcine mesenteric vascular preparations.

Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling

-blockers have evolved from anti-anginal drugs to effective therapeutics for various diseases, and may be useful in osteoporosis, cancer, and malaria in the future.

Previously unsuspected widespread cellular and tissue distribution of β-adrenoceptors and its relevance to drug action.

-adrenoceptors are found in various cell types, highlighting the need for understanding their role in various body tissues to develop new drugs.